<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03198312</url>
  </required_header>
  <id_info>
    <org_study_id>Branden-abc</org_study_id>
    <nct_id>NCT03198312</nct_id>
  </id_info>
  <brief_title>CathiportTM Clinical Efficacy and Safety Evaluation</brief_title>
  <official_title>a Prospective, Multicenter, Randomized, Open, Parallel Controlled Noninferiority Clinical Study to Evaluate the Efficacy and Safety of CathiportTM Implantable Drug Delivery Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong Branden Med.Device Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shandong Branden Med.Device Co.,Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Develop a prospective, multicenter, randomized, open, parallel controlled noninferiority&#xD;
      clinical trial to evaluate the efficacy and safety of CathiportTM implantable drug delivery&#xD;
      device&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      I-Port is also called the implantable infusion Port typed central venous catheter and suite,&#xD;
      it is a kind of the closed venous infusion system that can fully implanted, can be used for&#xD;
      all kinds of high concentrations of chemotherapeutic drugs, completely parenteral nutrient&#xD;
      solution infusion, blood transfusion and blood samples, It can be used to reduce painfulness&#xD;
      and the difficulty of repeated venipuncture, to prevent external stimulants weeks vein&#xD;
      injury, and the daily life of patients is not limited, they don't need to change medicine,&#xD;
      can bathe, so can improve the quality of life.&#xD;
&#xD;
      The purpose of the study is to evaluate the safety and efficacy of the CathiportTM. The&#xD;
      CathiportTM will be compared to an active control group represented by the FDA approved&#xD;
      commercially available Bard Implant Port.&#xD;
&#xD;
      The study consists of a randomized clinical trial (RCT) in China which will enroll&#xD;
      approximately 220 subjects (1:1 randomization CathiportTM : Implant Port) with patients&#xD;
      required repeated and chronic drug input and fluid.&#xD;
&#xD;
      All subjects in the RCT will be screened per the protocol required inclusion/exclusion&#xD;
      criteria. The data collected will be compared to data from the subjects enrolled into the&#xD;
      Implant Port of US RCT.&#xD;
&#xD;
      All subjects will have clinical follow-up at 1, 2, 3, 4, 5, 6 months and be provided nursing&#xD;
      service to t maintain he Port , and verify whether the pipe is blocked and to prevent the&#xD;
      Port into the liquid pipe clogging, and to observe the hematoma and infection situation of&#xD;
      the operation or puncture points, observe whether if there is blocking pipe, and fluid&#xD;
      extravasation surrounding skin tissue of judging when using, whether there are conditions&#xD;
      such as shift or discount.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">October 20, 2016</start_date>
  <completion_date type="Anticipated">January 20, 2018</completion_date>
  <primary_completion_date type="Anticipated">October 20, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Normal usage rate of the equipment</measure>
    <time_frame>at 6 months</time_frame>
    <description>The probability of normally drugs or liquid infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Success rate of equipment</measure>
    <time_frame>0 to 24 hours after implantation</time_frame>
    <description>Refers to the equipment can be get to the therapeutic part as expected successfully , the catheter can infused smoothly and the blood samples can be get back normally</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Success rate of surgery</measure>
    <time_frame>0 to 24 hours after operation</time_frame>
    <description>The fluid can be infused and withdraw normally, and no pneumothorax, air embolism, mediastinal hematoma surgical complications appeared</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the evaluation of the efficiency</measure>
    <time_frame>at 1,2,3,4,5,6 month</time_frame>
    <description>Catheter indwelling time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the evaluation of the convenience</measure>
    <time_frame>intraoperative</time_frame>
    <description>all the operaters will give a convenience evaluation timely by answering the questionnare</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the evaluation of the comfort</measure>
    <time_frame>intraoperative</time_frame>
    <description>physical performance evaluation of the device</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>CathiportTM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>be used for all kinds of high concentrations of chemotherapeutic drugs, completely parenteral nutrient solution infusion, blood transfusion and blood samples.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Implant Port</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>be used for all kinds of high concentrations of chemotherapeutic drugs, completely parenteral nutrient solution infusion, blood transfusion and blood samples.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CathiportTM</intervention_name>
    <description>fully implanted</description>
    <arm_group_label>CathiportTM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implant Port</intervention_name>
    <description>fully implanted</description>
    <arm_group_label>Implant Port</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Older than 18 years old;&#xD;
&#xD;
          2. Need for long-term intravenous fluids;&#xD;
&#xD;
          3. Lack of peripheral venous access ;&#xD;
&#xD;
          4. Need stimulants infusion, such as chemotherapy drugs;&#xD;
&#xD;
          5. Need infusion of high permeability or sticky liquid, such as parenteral nutrient&#xD;
             solution, fat emulsion;&#xD;
&#xD;
          6. Need repeated blood or blood products transfusion and repeated blood collection;&#xD;
&#xD;
          7. Fit and need implanted Port;&#xD;
&#xD;
          8. Willing to participate in clinical research and signed informed consent;&#xD;
&#xD;
        Patient meet 1 and 8 firstly, and then meet any one item with 2-7 above can be accepted.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Cancer patients whose vascular related to the surgery is compressed ;&#xD;
&#xD;
          2. Women patients with pregnancy and lactation;&#xD;
&#xD;
          3. Participate other studies before achieving the primary end point already;&#xD;
&#xD;
          4. Confirmed or suspected catheter-related infections, disseminated intravascular&#xD;
             coagulation, bacteremia, sepsis;&#xD;
&#xD;
          5. Body size is not suitable for implanting the infusion port ;&#xD;
&#xD;
          6. Confirmed or suspected allergic to silicone material;&#xD;
&#xD;
          7. Having a history of radiation therapy at the pre-implant site;&#xD;
&#xD;
          8. Having occurred acute myocardial infarction within 1 week or stroke in the past 6&#xD;
             months;&#xD;
&#xD;
          9. Having a history of venous thrombosis, trauma, or vascular surgery;&#xD;
&#xD;
         10. Superior vena cava syndrome;&#xD;
&#xD;
         11. Having poor compliance behavior;&#xD;
&#xD;
         12. Having installed the cardiac pacemaker device, bypass, accepted heart transplant or&#xD;
             diagnosed with kidney failure（GFR≤30ml/Min）.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>May 25, 2017</study_first_submitted>
  <study_first_submitted_qc>June 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2017</study_first_posted>
  <last_update_submitted>June 22, 2017</last_update_submitted>
  <last_update_submitted_qc>June 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

